Table 4.

Hypofractionation for prostate.

Trial	Sample Size	Inclusion Criteria	RT Technique	Fractionation	Outcomes	Median Follow-Up	Results
PROFIT [79]	1206	Intermediate-risk	3D/IMRT	78 Gy/39 fx 60 Gy/20 fx	BCF	6 years	5-year BCF DFS was 85% in both arms (HR [short v standard], 0.96; 90% CI, 0.77 to 1.2)
CHHIP [76,78]	3216	Localized prostate cancer (pT1b–T3N0) Mostly intermediate 73%	3D/IMRT	74 Gy/37 fx 60 Gy/20 fx 57 Gy/19 fx ADT allowed	Time to biochemical or clinical failure	5.2 years	5 yr BCF 74 Gy: 88.3% failure-free at 5 years. 60 Gy: 90.6%, HR vs. 74 Gy: 0.84, pNI = 0.0018. 57 Gy: 85.9%, HR vs. 74 Gy: 1.20, pNI = 0.48.

Legend: BCF: biochemical–clinical failure; HR: hazard ratio; fx: fractions; DFS: disease-free survival.